Payers aim to rein in specialty drug spending
Wall Street Journal (subscription required), March 21, 2008
Due to the rising expenditures for cancer drugs and other high-priced medicines, employers, health plans and pharmacy-benefit managers are increasing efforts to rein in spending. To curb use, payers are pushing for legislation to permit the sale of cheaper versions of biotech drugs. They are also reinforcing rules about trying cheaper therapies first and early certification of patients' prescriptions. Some are even suggesting paying drug companies based on how well a drug works, rather than how much is used.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- Carondelet to Pay $35M to Settle Fraud Allegations
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- CA Powers Up $80M HIE to 'Create Value in the Data'
- 3 Traits Personality Assessments Can't Reveal